Clinical Trials

Selecting a Favorable KIR Donor in Unrelated HCT for AML

Location:

Scottsdale and Phoenix,  AZ

Trial status:

Open for Enrollment

Why is this study being done?

Transplant Centers will select the best HLA matched, and as appropriate, preferred KIR donor.

Who is eligible to participate?

Inclusion Criteria:

- Patient with acute myeloid leukemia (AML) undergoing screening for potential URD HCT

- Potential URD undergoing screening to provide a HCT graft to a patient with acute myeloid leukemia (AML) at a participating institution

- Provides written consent

Last updated: 03/14/2013

NCT ID:

NCT01288222